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Abstract
In the past two years we observed several changes in 
the diagnostic and therapeutic approach of patients with 
acute heart failure (acute HF), which led us to the need of 
performing a summary update of the II Brazilian Guidelines 
on Acute Heart Failure 2009. 
In the diagnostic evaluation, the diagnostic flowchart 
was simplified and the role of clinical assessment 
and echocardiography was enhanced. In the clinical-
hemodynamic evaluation on admission, the hemodynamic 
echocardiography gained prominence as an aid to define 
this condition in patients with acute HF in the emergency 
room. In the prognostic evaluation, the role of biomarkers 
was better established and the criteria and prognostic value 
of the cardiorenal syndrome was better defined. 
The therapeutic approach flowcharts were revised, and 
are now simpler and more objective. Among the advances in 
drug therapy, the safety and importance of the maintenance 
or introduction of beta-blockers in the admission treatment 
are highlighted. Anticoagulation, according to new evidence, 
gained a wider range of indications. The presentation 
hemodynamic models of acute pulmonary edema were well 
established, with their different therapeutic approaches, as 
well as new levels of indication and evidence. In the surgical 
treatment of acute HF, CABG, the approach to mechanical 
lesions and heart transplantation were reviewed and updated. 
This update strengthens the II Brazilian Guidelines on 
Acute Heart Failure to keep it updated and refreshed. All 
clinical cardiologists who deal with patients with acute HF 
will find, in the guidelines and its summary, important tools 
to help them with the clinical practice for better diagnosis 
and treatment of their patients.
Introduction
Since the publication of the II Brazilian Guidelines on 
Acute Heart Failure in 2009, several advances have occurred 
regarding the diagnostic and prognostic capacity, as well 
as drug and nondrug therapy of acute HF. Due to this new 
information, the Department of Heart Failure of the Brazilian 
Society of Cardiology (Deic/SBC) carried out an executive 
summary update of this guideline.
The content of this summary update consists only of new 
information when compared to the 2009 guideline. What 
has not been published has been considered unaltered. 
Therefore, the reader should refer to the 2009 guideline to 
have access to the full content.
We added new indications for diagnosis and treatment of 
acute HF and reclassified several diagnostic and therapeutic 
methods, considering the new publications in the last two years.
Clinical diagnosis 
The diagnostic evaluation of acute HF should be 
performed systematically within the first hours of admission 
at the emergency room. The diagnosis of acute HF is based 
on clinical signs and symptoms of pulmonary or systemic 
congestion, associated or not with the presence of low 
cardiac output supported by diagnostic tests. The presence 
of fatigue or hypovolemia should also be assessed. During the 
anamnesis and clinical examination, one must also establish 
whether the acute HF is of recent onset (New acute HF) or 
a case of acute chronic HF, as well as the likely causal and 
triggering factor of acute decompensated HF, the possible 
associated diseases and drugs that have been used. By 
analyzing the presence of congestion and low output, the 
clinical and hemodynamic evaluation is performed and, 
finally, the patient risk profile is assessed and the therapeutic 
targets to be achieved are defined. 
- The use of systematic diagnostic evaluation is 
recommended, through Framingham or Boston criteria, for 
the diagnosis of acute HF.
Class of recommendation I, Level of evidence B
Ecocardiograma
Admission assessment through two-dimensional 
echocardiography is used for analysis of systolic and diastolic 
function of left and right ventricles, hemodynamic estimates, 
in addition to valve involvement assessment and to estimate 
the likely causal factor. 
Class of recommendation I, Level of evidence B
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Other non-invasive and invasive examinations
Cardiac magnetic resonance imaging
When using the late gadolinium enhancement technique 
as a contrast, one can obtain information on inflammation, 
infiltrative processes and areas of edema or fibrosis, being 
useful in the investigation of myocarditis, myocardial infarction 
scars, pericardial diseases, cardiomyopathies, infiltrative and 
storage diseases. Limitations include patients with pacemakers, 
ocular or intracranial metallic clips and patient intolerance.
For the investigation of myocarditis and etiology, as well as 
assessment of cardiac volumes, when the echocardiography 
is not conclusive.
Class of recommendation I, Level of evidence B
Pulmonary Function Tests 
They can be useful to exclude lung diseases as the cause 
of dyspnea. Their use in acute HF, however, is limited, as the 
presence of congestion can influence results.
Class of recommendation III, Level of evidence C
Coronary angiography
It is indicated in cases of acute coronary syndrome as a 
cause of HF. The reperfusion strategy (percutaneous or surgical) 
must be considered in appropriate patients, being related to 
the improved prognosis1.
Class of recommendation I, Level of evidence B
Pulmonary artery catheter
The use of a pulmonary artery catheter is usually not 
necessary for the diagnosis of HF. It may be useful to 
differentiate cardiogenic from non-cardiogenic shock in 
complex patients or in the presence of associated lung disease. 
Class of recommendation IIb, Level of evidence B
Clinical and hemodynamic evaluation of patients with 
acute HF
Hemodynamic echocardiogram 
In the context of acute HF, the echocardiography can detect and 
define hemodynamic alterations, quantifying intracavitary pressures 
and guiding therapy in an equivalent way to invasive methods2,3.
- Hemodynamic assessment of acute HF through 
hemodynamic echocardiography.
Class of recommendation I, Level of evidence B
Transthoracic bioimpedance (TB)
Hemodynamic evaluation by TB in patients with acute HF 
is superior to clinical evaluation in the diagnosis of pulmonary 
congestion (PC) and low cardiac output, and the value of lung 
water > 18 was a strong predictor of BNP > 200 pg/mL in 
the diagnosis of PC4.
Figure 1 - Flowchart of the initial investigation of patients with acute HF.
Flowchart of the initial management of patients with acute HF  (Figure 1)
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- Evaluation by transthoracic bioimpedance for diagnosis 
of acute HF. 
Class of recommendation IIb, Level of evidence B
- Evaluation by transthoracic bioimpedance to optimize 
treatment of acute HF. 
Class of recommendation IIb, Level of evidence B
Chest Ultrasonography
The chest ultrasonography allows the differential diagnosis 
of pulmonary congestion and chronic obstructive pulmonary 
disease by analyzing the B-lines of congestion (comet-tails), 
and A-lines in COPD. B-lines have a sensitivity of 97% and 
specificity of 95% for the diagnosis of pulmonary congestion5.
- Differential diagnosis of dyspnea in the emergency room 
by chest ultrasonography. 
Class of recommendation IIb, Level of evidence C
Invasive monitoring 
Placement of invasive blood pressure catheter (arterial line)
To monitor the mean arterial pressure, usually through 
radial or femoral access: 
- Hemodynamic instability necessitating the use of 
vasopressor amines;
- Necessity to collect frequent arterial blood gas samples;
- Use of intravenous sodium nitroprusside for clinical 
compensation.
Class of recommendation IIa, Level of evidence C
Placement of central venous catheter (venous line)
- Need for vasopressors (especially norepinephrine);
- To monitor central venous oxygen saturation (SVO2) 
when indicated;
- To monitor central venous pressure.
Class of recommendation IIa, Level of evidence C
Placement of a pulmonary artery catheter (Swan-Ganz) 
- To evaluate the hemodynamic routine: the use of 
pulmonary artery catheter in the assessment of all patients 
with acute HF should not be performed.
Class of recommendation III, Level of evidence C
Targets in the treatment of acute HF
The treatment of acute HF should be aimed at patient 
optimization by reaching clinical, hemodynamic and 
metabolic targets shown in Table 1. 
- Establish therapeutic targets to guide treatment of patients 
with acute HF. 
Class of recommendation I, Level of evidence C
Markers of risk profile and prognosis in acute HF
Cardiac markers and echocardiography 
BNP/N-proBNP
Retrospective studies and data from international registries 
have shown that high levels during hospitalization and at 
hospital discharge of BNP (> 750 ng/dL) and its precursor 
NT-proBNP are independent predictors of mortality 
and rehospitalization6,7.
Class of recommendation IIa, Level of evidence B
Troponins
Retrospective studies and the ADHERE registry have 
identified that alterations in serum levels of troponin T and 
I > 0.01 mg/dL are independent predictors of poor in-hospital 
and after discharge prognosis.
Class of recommendation IIa, Level of evidence B
Ecocardiografia
In the setting of acute HF, echocardiography provides 
parameters that help in risk stratification, such as ejection 
fraction, left ventricular diameter, pulmonary pressure, filling 
pressures and cardiac output. 
Class of recommendation I, Level of evidence B
Table 1 - Targets in the treatment of acute HF
Early phase :
Decrease signs and symptoms of congestion in 6 
hours
Adequate oxygenation (SatO2 > 90%)
Maintain adequate diuresis: > 0.5 mL//Kg/h
Prevent SBP < 90 mmHg
Reverse hemodynamic disorder 
Late phase:
Prevent rehospitalization
Decrease mortality
Decrease hospital stay duration
Laboratory:
Electrolytic normalization 
Prevent creatinine increase > 0.3 mg/dL
Decrease BNP
Decrease troponin
Decrease CRP
Hemodynamic:
Decrease filling pressures 
(by echocardiogram or bioimpedance)
Optimize cardiac output
(By echocardiogram or bioimpedance)
Metabolic:
Arterial lactate normalization 
SVO2 >70%
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Cardiorenal syndrome 
When the acute kidney injury results from acute cardiac 
dysfunction, it is called cardiorenal syndrome type 1 and 
is present in 30% to 50% of patients hospitalized with 
acute HF8,9. The criterion for diagnosis is the increase in 
serum creatinine ≥ 0.3 mg/dL or an increase > 50% of the 
hospital admission one. Other biomarkers such as NGAL and 
Cystatin-C have a greater capacity for early detection of kidney 
injury in the context of acute HF than creatinine and urea10. 
- Monitoring of renal function with NGAL or Cystatin C to 
detect cardiorenal syndrome. 
Class of recommendation IIb, Level of evidence B
Risk profile 
Other scores of mortality
In addition to the ADHERE 11 score, two other in-hospital 
acute HF mortality risk scores have been published more 
recently: OPTIMIZE 12 and GWTG-HF 13. 
- Use of risk scores for prognostic risk stratification of 
patients with acute HF at hospital admission. 
Class of recommendation I, Level of evidence A
Acute HF Treatment
The rationale of the therapeutic approach in acute HF is 
established from the combination of three main factors: the 
development model of acute HF with causal factor + BP + 
clinical and hemodynamic assessment. This rationale establishes 
the flow charts of the therapeutic approach (figures 2, 3, 4):
Clinical Treatment
Intravenous medications in the acute phase and during 
hospitalization
Diuretics 
Oral and intravenous diuretics in acute HF: dose and dose 
interval  (table 2).
Use of furosemide at 4-hour intervals or continuous infusion 
in cases of unsatisfactory response or severe systemic congestion. 
Continuous infusion with an initial dose of 10 mg/h, with 10-20 
mg increases, preceded by infusion of 10 mg in bolus.
Class of recommendation I, Level of evidence B
The use of hypertonic saline  solution associated with 
furosemide (NaCl 4.6% to 7.5%, 100 to 150 ml, infused 20-
30 minutes) may be considered for hyponatremic patients 
refractory or not to the initial treatment.
Class of recommendation IIa, Level of evidence B
Intravenous vasodilators
- Nesiritide
Recently, a large randomized trial (ASCEND-HF) showed 
that nesiritide does not reduce mortality in patients with 
acute HF, improving dyspnea, with no increase in serious 
adverse events, which limits its routine use due to the 
current cost of the medication, even though it is the most 
studied vasodilator14.
- For the treatment of acute HF in patients without 
hypotension.
Class of recommendation IIb, Level of evidence A
Figure 2 - Stratification of mortality risk of patients with acute HF according to the epidemiological data of the ADHERE registry.
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Fig. 3 - Flowchart of therapeutic rationale of new acute HF.
Fig. 4 - Flowchart of therapeutic rationale of acute chronic HF.
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Volume replacement
Dynamic evaluation methods of cardiovascular 
responsiveness to volume
- Spontaneous ventilation
The inspiratory variation of CVP ≥ 1 mmHg15, the increase 
in aortic flow and/or blood pressure and/or CVP after passive 
elevation of the lower limbs (45o)16,17 and increased pulse 
pressure variation through the Valsalva maneuver have high 
accuracy in the identification of responsive patients.
Class of recommendation IIa, Level of evidence C
- Mechanical ventilation 
Inspiratory variation of CVP, systolic volume, aortic flow, 
arterial pulse pressure, pulse plethysmography and vena cava 
collapse index allow the reliable assessment of cardiovascular 
responsiveness in mechanically ventilated patients without 
cardiac arrhythmias18,19.
Class of recommendation IIa, Level of evidence C 
Oral medications in the acute phase and during 
hospitalization
Digitalis
The use of digitalis in acute HF has not been tested in 
randomized clinical trials. Digitalis has been recommended 
as an aid to beta-blockers, or even before its introduction in 
the control of HR in patients with decompensated HF with 
systolic dysfunction, atrial fibrillation and ventricular response 
> 80 bpm. Its use should be avoided in patients with acute 
coronary artery disease. Dosage: 0.4 mg in 100 ml of saline 
solution, infused over 30 minutes. 
Class of recommendation IIa, Level of evidence C
Beta-blockers
Beta-blockers (BB) should be introduced at hospital 
admission in patients with acute HF who were not previously 
using it, or maintained in those with previous use, as clinical 
benefits have been demonstrated in reducing in-hospital and 
outpatient mortality, with lower readmission rates, with no 
clinical or hemodynamic worsening of patients and led to 
higher rate of prescription at discharge20-22. 
When inotropic support is necessary, levosimendan and 
phosphodiesterase inhibitor (Milrinone)23,24, as they do not 
suffer BB antagonism, are more suitable. Dobutamine shows 
partial reduction of its effects and may have deleterious 
hemodynamic action in patients using carvedilol25.
BB should be started at low doses and can be adjusted 
every 3-5 days; the development of hypotension, bradycardia, 
worsening of pulmonary congestion, low cardiac output or 
impaired renal function must be verified. In these situations, 
one must return to the previous dose and stop the progression 
of BB. The presence of clinical conditions such as anemia, 
hypovolemia, excessive vasodilator dose and inflammatory 
states predisposes to the development of hypotension with 
the use of BB.
BB with proven benefits in acute HF are bisoprolol, 
carvedilol and metoprolol succinate. The others have not been 
used in clinical studies in patients with acute HF. 
Indications of the use of beta-blockers in acute HF
- Start or maintain the BB in patients with no evidence of 
hypotension or low cardiac output.
Class of recommendation I, Level of evidence A
- Reduce the dose of BB by 50% or withdraw it at the 
admission in patients with signs of low cardiac output without 
arterial hypotension. 
Class of recommendation I, Level of evidence B
- Reduce the dose of BB by 50% in patients with 
hypotension without low cardiac output. 
Class of recommendation IIa, Level of evidence C
- Withdraw BB in patients with cardiogenic or septic 
shock, critical aortic stenosis, decompensated asthma, 
advanced atrioventricular block. 
Class of recommendation I, Level of evidence C
Table 2 - Classes, mechanism of action, initial and maximum dose of diuretics in acute HF  
Diuretics Initial dose (mg) Maximum dose (mg) Interval (h)
Loop Diuretics:
• Furosemide
• Bumetanide
20
0.5 – 2.0
240
10
4/4;6/6;12/12
6/6
Thiazide
• Hydrochlorothiazide
• Chlorthalidone 
• Indapamide
25
12.5
2.5
100
50
5.0
24/24 - 12/12
24/24
24/24
Potassium-sparing diuretics:
• Spironolactone
• Amiloride
• Triamterene
25
2.5
25
50
20
100
24/24
24/24
24/24
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ACE Inhibitors/ARBs
In the presence of clinical situations of hypovolemia, 
hyponatremia, anemia, inflammatory states, or sepsis due 
to the potential development of hypotension or worsening 
of renal function, the introduction of ACE inhibitors or ARBs 
should be postponed for the correction of these disorders26,27 . 
In patients with LV dysfunction after MI, there is enough 
evidence to suggest the early use of ACE inhibitors in all 
patients without contraindications28-30.
ARBs have been extensively tested against ACE inhibitors, 
but there is no evidence of superiority of one agent over 
another31,32. Their main indication is for patients who cannot 
tolerate ACE inhibitors because of coughing.
Indications and levels of evidence of ACEI and ARB use in 
acute HF
- Start or maintenance of ACE inhibitors in the absence 
of signs of low output or symptomatic arterial hypotension. 
Class of recommendation I, Level of evidence A
- Start or maintenance of ARB in the absence of signs of 
low output or symptomatic hypotension. 
Class of recommendation I, Level of evidence B
Spironolactone
- Use of spironolactone in HF FC III and IV with EF < 35% 
after the use of intravenous diuretics. 
Class of recommendation I, Level of evidence B  
Full and prophylactic anticoagulation in acute HF
- Use of anticoagulation with LMWH or UFH in patients 
with decompensated HF in the presence of atrial fibrillation, 
identification of intracavitary thrombus, mechanical valve 
prosthesis, with or without ventricular dysfunction 33,34.
Class of recommendation I, Level of evidence A
- Use of full anticoagulation with LMWH or UFH associated 
with antiaggregant agents in patients with decompensated HF 
with acute coronary syndrome35.
Class of recommendation I, Level of evidence A
- Use of prophylactic anticoagulation with LMWH or 
UFH in patients with decompensated HF, peripartum 
cardiomyopathy, myocardial noncompaction36. 
Class of recommendation I, Level of evidence C
- Prophylaxis of DVT, with low-dose unfractionated heparin 
or low molecular weight heparin, during confinement in bed37.
Class of recommendation I, Level of evidence B
- In patients with kidney dysfunction (creatinine clearance 
< 30 mL/min), avoid the use of LMWH, the preferential use 
of UFH is recommended. 
Class of recommendation I, Level of evidence B
- Use of full anticoagulation with LMWH or UFH in patients 
with severe ventricular dysfunction. 
Class of recommendation IIb, Level of evidence C
Specific situations 
Acute Pulmonary Edema (APE)
APE has two distinct hemodynamic models of volume 
distribution: 
1) Pulmonary congestion with peripheral hypovolemia 
observed in pictures of new acute HF in patients with no prior 
HF and normal blood volume. Treatment aims to redistribute 
the volume of pulmonary circulation into the peripheral 
circulation by the action of arterial vasodilators associated 
with ventilatory support with noninvasive positive pressure. It 
is not intended as priority the use of large doses of diuretics, 
as they can induce low cardiac output by reducing the right 
ventricular preload38.
- Restricted use of diuretics in APE for new acute HF: 
Class of recommendation IIa, Level of evidence B
2) Pulmonary and systemic congestion, observed in patients 
with aggravated acute chronic HF. Treatment priority is the 
reduction of blood volume through the large-scale use of 
diuretics associated with vasodilators for the improvement of 
ventricular function and sometimes, inotropic agents, in the 
presence of low cardiac output. 
- Unrestricted use of intravenous diuretics in APE due to 
acute chronic HF:
Class of recommendation IIa, Level of evidence B
- The noninvasive ventilatory support with positive pressure 
is associated with reduced respiratory load and pulmonary 
congestion, with consequent improvement in dyspnea and 
decreased need for orotracheal intubation and mechanical 
ventilatory support.
- Noninvasive ventilatory support with positive pressure on 
admission of patients with no evidence of respiratory failure: 
Class of recommendation I, Level of evidence B 
- Orotracheal intubation is indicated in the presence of 
respiratory failure (invasive mechanical ventilatory support). 
Class of recommendation I, Level of evidence B
- The use of opioids has shown benefits in reducing 
adrenergic activity with a consequent reduction in systemic 
vascular resistance and respiratory load. One should be cautious 
in situations of relative hypovolemia as in new acute HF39.
Class of recommendation I, Level of evidence B
Invasive treatment of acute HF 
Myocardial Revascularization  (MR)
Recommendations for MR 
- Early, percutaneous or surgical MR is indicated in the 
presence of acute HF with ongoing ischemia40.
Class of recommendation I, Level of evidence B
Pereira et al.
Summary of the II Brazilian Guideline on Acute Heart Failure 
381
Special Article
Arq Bras Cardiol 2012;98(5):375-383
- Early MR is indicated in patients with AMI who develop 
cardiogenic shock in the presence of critical coronary lesion 
that can be treated41.
Class of recommendation I, Level of evidence B
Early MR in patients with left ventricular dysfunction and 
hemodynamic instability, with significant mass of viable, non-
contractile myocardium and favorable anatomy42.
Class of recommendation IIa, Level of evidence B
Recommendations for the management of the patient with 
mechanical complications of AMI 
- The surgical treatment of mechanical complications of 
acute myocardial infarction should be performed early to 
prevent hemodynamic deterioration, despite the use of intra-
aortic balloon 3.
Class of recommendation I, Level of evidence B
- The implant of mechanical circulatory support is 
indicated in patients with hemodynamic instability despite 
inotropic support44.
Class of recommendation IIa, Level of evidence C
- MR associated with left ventricular reconstruction 
can be recommended in patients with HF and fibrosis in 
the region corresponding to the territory of the anterior 
interventricular artery45.
Class of recommendation IIb, Level of evidence B
- The routine use of assistance with a centrifugal pump is 
not recommended46.
Class of recommendation III, Level of evidence B
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